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Abstract We have investigated seven patients with the
type B form of pyruvate carboxylase (PC) deficiency.
Mutation analysis revealed eight mutations, all novel. In a
patient with exon skipping on cDNA analysis, we identified
a homozygous mutation located in a potential branch point
sequence, the first possible branch point mutation in PC.
Two patients were homozygous for missense mutations
(with normal protein amounts on western blot analysis),
and two patients were homozygous for nonsense mutations.
In addition, a duplication of one base pair was found in a
patient who also harboured a splice site mutation. Another
splice site mutation led to the activation of a cryptic splice
site, shown by cDNA analysis.
All patients reported until now with at least one missense
mutation have had the milder type A form of PC deficiency.
We thus report for the first time two patients with
homozygous missense mutations with the severe type B
deficiency, clinically indistinguishable from other patients
with type B form of PC deficiency.
The mutations found here are novel; it is noteworthy that
four Turkish patients did not have any mutations in
common, despite the rarity of PC deficiency. There is thus
no evidence for recurrent mutations in the Turkish or other
populations.
Pyruvate carboxylase (PC) deficiency (MIM #262150) is a
rare autosomal recessive disorder with an incidence of
around 1 in 250,000. It is caused by deficiency of the
pyruvate carboxylase enzyme, which is encoded by PC. PC
is a mitochondrial matrix enzyme that converts bicarbonate
and pyruvate to oxaloacetate, which is used by phospho-
enolpyruvate carboxykinase and by the Krebs cycle. The
enzyme has important functions in gluconeogenesis, where
it is considered the major regulatory enzyme, and it is also
involved in lipogenesis and biosynthesis of neurotransmit-
ters. PC forms a homotetramer with each subunit having
one molecule of biotin covalently attached. Mutations in
genes involved in biotin metabolism may cause a secondary
deficiency that can be treated with biotin supplementation,
whereas PC deficiency is not responsive to biotin therapy.
The clinical presentation of pyruvate carboxylase defi-
ciency has been divided into three groups, with some
overlap between the groups (Robinson 2001; Marin-
Valencia et al. 2010). Group A patients present with lactic
acidosis between birth and 5 months of age, and survival up
to 5 years. The biochemical parameters are generally
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normal, except for elevated alanine and proline. The most
prominent symptom is psychomotor retardation. Group B
patients have a more severe clinical presentation with
neonatal onset of lactic acidosis and neurological symp-
toms, and death within 3 months. The biochemical
parameters are severely abnormal, including elevated
lactate/pyruvate and acetoacetate/b-hydroxybutyrate ratios,
and elevated citrulline, lysine, proline, alanine and blood
ammonia. In both forms, hepatomegaly, seizures and failure
to thrive may occur. In addition, a few patients with a mild
form of PC deficiency, group C, have been reported.
Here we report the clinical and molecular results,
including eight novel mutations, in seven patients with the
severe type B form of PC deficiency, referred to our
laboratory from 1992 to 2011. Pyruvate carboxylase
activity was measured in cultured fibroblasts as described
(Hansen and Christensen 1980). DNA and total RNA was
extracted by standard methods from cultured fibroblasts
with compromised PC activity and the RNA was reverse
transcribed by SuperScript II (Invitrogen). The cDNA
sequence of PC was PCR amplified (GoTaq PCR kit
Promega), purified (ExoZap, Finnzymes) and sequenced
(Big Dye Terminator V1,1 (Applied Biosystems)). The
genomic sequence of PC was assessed in a similar manner
(Primers and conditions are available upon request).
Mitochondria were isolated from cultured fibroblasts as
previously reported (Sch€agger et al. 1994). For electropho-
resis, 10 mg of protein was run on a 9 % SDS acrylamide
gel, which was blotted onto a PVDF membrane. Mitochon-
drial biotin–containing proteins (pyruvate carboxylase, the
a subunit of 3-methylcrotonyl-CoA carboxylase and the a
subunit of propionyl-CoA carboxylase) were detected with
HRP-conjugated avidin (Sigma) at a 1:10,000 dilution and
Supersignal West Pico substrate (Pierce) (Singh et al.
2005). The blot was exposed to film and developed.
Seven patients were identified with severely decreased
PC activity (Table 1). The clinical data are shown in
Table 1. All patients had the type B form of PC deficiency
with an uneventful pregnancy and birth, and a birth weight
in the low to normal range. As in other type B patients, the
presenting symptom was most often respiratory distress or
lactic acidosis, and eventually all patients developed lactic
acidosis, and most patients developed respiratory distress.
Additional symptoms previously seen in type B patients
were also found in some of the patients reported here:
seizures, liver affection, hypo- and hypertonia and dys-
morphism. Brain imaging showed bilateral cystic changes
in four patients; additional findings were cortical atrophy
and leukodystrophy. Plasma citrulline was measured in
three patients and found to be elevated in all three. Type B
patients usually die within the first 3 months; this was also
the case for five of the patients reported here, whereas two
of the seven patients survived until 5 months of age.
The mutation analysis revealed eight different mutations,
all novel (Table 2). Four of the seven patients were
homozygous for PC mutations, and three were compound
heterozygous.
cDNA analysis of patient 1 showed activation of a cryptic
splice site at position c.903+8_9 leading to retention of the
first seven nucleotides of intron 8 and thus a change of the
correct reading frame and a premature stop codon (Fig. 1a).
Analysis of genomic DNA revealed the heterozygous
presence of a splice site mutation, c.903+1G>A, at the
exon 8 donor site. The cDNA analysis of patient 1 also
displayed complete skipping of exon 12. Subsequent
genomic analysis of the coding sequence, including ~ 600 bp
upstream of exon 12, exon 12 and the entire intron 12
(amplified as one fragment), did not reveal any pathogenic
mutations. The patient was, however, heterozygous for a
known SNP in intron 11, c.1369-529g>a (rs2077432),
arguing against a genomic deletion of exon 12. We
therefore suspect that the exon 12 skipping is most likely
due to an intronic mutation further upstream in the large
intron 11 (intron size: ~11 kb).
In patient 2, only trace amounts of PC cDNA could be
generated, but direct genomic sequencing showed com-
pound heterozygous presence of a c.3436dupG mutation,
leading to a frameshift, and c.3288+1G>A, expected to
compromise correct splicing. Both mutations probably
activate the nonsense-mediated mRNA decay (NMD)
pathway.
Patients 3 and 4 were homozygous for two different
nonsense mutations, c.1240C>T (p.Gln414X) in exon 9
and c.370C>T in exon 3 (p.Arg124X), respectively.
Patient 5 was homozygous for a missense mutation in
exon 4, c.615G>C (p.Arg205Ser). p.Arg205 is highly
conserved among species (Fig. 1b) and changes a charged
arginine to an uncharged serine. It is located in the biotin
carboxylation domain of the protein, where two other
missense mutations have been found (Monnot et al. 2009).
In patient 6, a homozygous missense mutation in exon
16, c.2606G>A (p.Gly869Asp), was found. The affected
amino acid residue is located in the carboxyl transferase
domain of the protein, and the mutation changes a highly
conserved nonpolar glycine to a polar aspartic acid. The
absence of other mutations, the severely decreased activity
of PC and the normal amounts of PC protein on western
blot makes it highly likely that both p.Arg205Ser and
p.Gly869Asp are pathogenic.
In patient 7, cDNA analysis encompassing exons 8 to 14
revealed two abnormal fragments of 684 bp and 897 bp
(Fig. 1a), but no product of the expected normal size
(829 bp). The 684 bp fragment corresponded to a skipping
of exon 12, whereas the 897 bp fragment showed retention
of the last 68 bp of intron 11, most likely due to an
activation of a cryptic splice acceptor site at position
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c.1369–69_70. By genomic analysis of exon 12 and
~600 bp of intron 11 we identified a homozygous
substitution in intron 11, c.1369-29A>G. The mutation
affects a highly conserved adenine in a stretch of five
nucleotides (GTGAC) with strong resemblance to the
consensus branch point sequence Py79 T75 N A92 Py75
(79 % of nucleotides are pyrimidine, 75 % thymine, any
nucleotide, 92 % adenine, 75 % pyrimidine), except for the
first nucleotide, which is a purine (guanine). The possible
branch point sequence is located 32–28 bp upstream of the
splice acceptor site (consensus 34–21 bp) of exon 12
(Fig. 1c) (Gao et al. 2008).
As expected, western blot analysis showed absence of
PC protein in the five patients who had nonsense,
frameshift or splicing mutations, whereas normal amounts
were found in patients 5 and 6 with missense mutations
(Fig. 1d).
This paper adds eight additional mutations to the mutation
spectrum in the type B form of PC deficiency. Only a few
mutations have been reported previously in patients with the
type B form of PC deficiency: four frameshift mutations, an
intron retention mutation, a splice site mutation and two
missense mutations (Monnot et al. 2009; Carbone et al.
2002; Wexler et al. 1998). All patients reported until now
with at least one missense mutation have had the milder
type A form of PC deficiency, probably due to an, albeit
low, residual activity. We thus report for the first time two
patients with homozygous missense mutations with the
severe type B deficiency, clinically indistinguishable from
the other patients with type B form of PC deficiency.
Table 2 Mutations in seven patients with PC deficiency
Patient Nucleotide change Amino acid change Mutation type
PC protein on western
blot analysis
1 c.903+1G>A/? Exon skipping/Exon skipping Splice site/? Absent
2 c.3288+1G>A/c.3436dupG Exon skipping/?p.Glu1146GlyfsX26 Splice site/Frameshift Absent
3 c.1240C>T/c.1240C>T p.Gln414X/p.Gln414X Nonsense Absent
4 c.370C>T/c.370C>T p.Arg124X/p.Arg124X Nonsense Absent
5 c.615G>C/c.61G>C p.Arg205Ser/p.Arg205Ser Missense Normal
6 c.2606G>A/c.2606G>A p.Gly869Asp/p.Gly869Asp Missense Normal
7 c.1369-29a>g/c.1369-29a>g Intron retention and exon skipping Branch point Absent
Fig. 1 Analysis of PC protein and sequence analysis. (a) cDNA
analysis of an exon 8–14 fragment. The normal size fragment of
829 bp is seen in the control (C), whereas a fragment of 684 bp with
skipping of exon 12 is seen in patients 1 and 7. Patient 1 also has a
band of 836 bp, which corresponds to a fragment with retention of
the first 7 nucleotides of intron 8, caused by a splice site mutation,
c.903+1G>A. The band of 897 bp in patient 7 represents a fragment
with retention of the last 68 bp of intron 11. The intensity of the
cDNA fragments in patients 1 and 7 is likely a consequence of
activated NMD pathway. (b) Alignment of PC showing the conserva-
tion of the missense mutations found in patients 5 (p.Arg205Ser) and
6 (p.Gly869Asp). (c) The genomic sequence of exon 12 and the
flanking ~40 bp of intron 11. The c.1369-29A>G mutation (in bold)
is located in a potential branch point sequence (boxed). (d) Western
blot analysis of protein from fibroblast mitochondria with HRP-
conjugated avidin. C: control. 1–7: patients 1–7. The a subunit of
3-methylcrotonyl-CoA carboxylase (3-MCC) and the a subunit of
propionyl-CoA carboxylase were used as loading controls
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In addition, we report for the first time a possible branch
point mutation in PC. The branch point is an element that,
together with the polypyrimidine tract, the 50 and 30 splice
sites and exonic/intronic splicing enhancers/silencers, is
essential for correct pre-mRNA splicing, and branch point
mutations typically lead to exon skipping, intron retention
or the use of a cryptic 30 splice site, in accordance with our
findings of exon skipping and intron retention.
All the mutations found here are novel; it is noteworthy
that the four Turkish patients did not have any mutations in
common, despite the rarity of PC deficiency. A founder
mutation has been found in Canadian Indians (Carbone
et al. 1998), but the mutation has not been reported in other
populations, where different mutations are found with all
families having their private mutation(s). There is thus no
evidence for recurrent or founder mutations in other
populations, including the Turkish population.
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